Compare MLYS & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLYS | FAX |
|---|---|---|
| Founded | 2019 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 589.9M |
| IPO Year | 2023 | N/A |
| Metric | MLYS | FAX |
|---|---|---|
| Price | $28.26 | $14.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $48.67 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 199.6K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.09% |
| EPS Growth | ★ 37.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.44 | $14.18 |
| 52 Week High | $47.65 | $16.95 |
| Indicator | MLYS | FAX |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 39.38 |
| Support Level | $26.85 | N/A |
| Resistance Level | $30.53 | $15.62 |
| Average True Range (ATR) | 1.53 | 0.27 |
| MACD | 0.61 | -0.03 |
| Stochastic Oscillator | 85.99 | 27.69 |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.